Votrient effectiveness has been reported by a number of research studies including clinical trials. Votrient effectiveness is usually noticed in terms of response rate, progression free survival and tumor shrinkage and these properties are well documented in favor of Votrient.
Votrient benefits include a good degree of tolerability, relatively less side effects especially chances for cytopenia are quite low with Votrient, better response rate, and increased progression free survival. One of the important Votrient benefits is oral administration which makes its treatment easier.
Votrient results characterize a significant prolonging of progression free survival in all patients. Other important features of Votrient results included more robust response in treatment naïve patients as compared to the patients which previously undergone cytotoxic therapy .
Clinical activity of Votrient depicting Votrient efficacy has been noticed in kidney, thyroid, breast, cervical, liver, lung, prostate, and colorectal cancer. Votrient efficacy has also been observed against melanoma and glioblastoma. Though, it has sought approval for kidney cancer, clinical trials are underway for several other types .
Votrient response rate was assessed in the Phase III of clinical trials that led to the approval of this drug. This trial was based on the 435 renal cell carcinoma patients. Votrient response rate noted in this study was 32% for treatment naïve patients with a median time of 58.7 weeks .